For investors only

All about the drug candidate arfolitixorin
and related information

Isofol´s history

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.

Isofol’s operations are based in Gothenburg, and the company’s shares traded on Nasdaq Stockholm’s main market in the Mid Cap segment.

Last updated 05-24-2024